A polarizing ALS drug headed for FDA scrutiny; FTC files antitrust suit over alleged anesthesiology monopoly

Taking stock of the drug industry, from the lab to the medicine chest

September 21, 2023 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Adobe STAT+ | What to know about the polarizing ALS drug headed for FDA scrutiny next week Critics want more data on stem-cell therapy NurOwn. ALS advocates say the needs of patients should be top priority in approving new drugs. By Damian Garde STAT+ | Travere kidney drug narrowly fails confirmatory trial following FDA approval Travere Therapeutics had received FDA accelerated approval for Filspari, a drug to slow the loss of kidney function from IgA nephropathy. Stock price drops. By Jason Mast FTC sues private equity firm Welsh Carson, U.S. Anesthesia Partners for allegedly creating a monopoly Federal Trade Commission says U.S. Anesthesia Partners and its private equity owner, Welsh, Carson, Anderson & Stowe, tried to raise prices, boost profits. By Bob Herman and Tara Bannow Constanza Hevia for STAT STAT+ | They carry a gene for ALS but aren't sick. What does medical research owe them? A new movement is pushing the medical and research world to include people with genetic mutations for ALS for the first time. By Jason Mast STAT+ | Bernie Sanders, Bill Cassidy clash over proposal to increase primary care doctors, nurses Sens. Bernie Sanders and Bill Cassidy clashed over a proposal to increase the number of primary care doctors and nurses in the United States. By Rachel Cohrs STAT+ | Thermo Fisher just opened a $180 million plant. Executives already are talking about expanding. Thermo Fisher's plant to manufacture gene therapies for drug companies is a year old, but executives are already talking about expanding. By Jonathan Saltzman — Boston Globe A thorny ALS debate at the FDA, and the promise of artificial wombs STAT's Lizzy Lawrence joins us this week to explain the promise of artificial wombs and the debate over how to ethically develop them. By Damian Garde and Allison DeAngelis

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2023, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser